Hangzhou Ruomai Xing Pharmaceutical Technology

Hangzhou Ruomai Xing Pharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company focuses on leveraging molecular glue and PROTAC technologies to address undruggable targets in oncology and immunology. Founded by industry veterans with expertise in medicinal chemistry and protein science, Ruomai Xing aims to create highly selective small molecule degraders. The company has secured significant venture capital funding to advance its proprietary platform and early-stage pipeline. Its research efforts are centered on identifying novel E3 ligase ligands and optimizing degrader molecules for clinical efficacy. Ruomai Xing is positioned as an emerging player in the rapidly evolving field of protein homeostasis.